Investigating the essential roles of Ubiquitin-like molecules and the Ubiquitin Proteasome System
• 1985-1990 Research Fellow at the Department of Biochemistry and Molecular Biology I, Universidad Complutense, Madrid.
1985-1986 Graduate Research Project on “Enzymology of pulmonary surfactant”
1987-1990 Ph.D. Research Project on “Study of the catalytic mechanism of penicllin acylase from Kluyvera citrophila" (collaborative programme with Antiobioticos Farma, S.A.)
1986-1989 Teaching Assistant in Biochemistry, Faculty of Biology, Universidad Complutense de Madrid.
1989 (Jul-Sep) Research Fellow in the Department of Biochemistry and Genetics, The University of Newcastle upon Tyne, UK.
During the years in the University, I acquired training and background in enzymology and protein biochemistry. I was involved in the elucidation of the kinetic and catalytic mechanism of enzymes, as well as the mechanism of action of enzyme inhibitors.
• 1990-2001 Research Scientist and Head of Laboratory, Research Department, Glaxo/Glaxo Wellcome (Tres Cantos, Spain)
I contributes to set up the infrastructure and scientific programmes of the Biology Section of the newly established Research Department of Glaxo Spain, which was devoted to the discovery of new antimicrobials (i.e. antibacterials, antifungals and antiprotozoans).
• Jul2001-Now Manager and Director of Screening & Compound Profiling, GlaxoSmithKline (Tres Cantos, Spain)
I am currently working at the Molecular Discovery Research automation facility of GlaxoSmithKline in Tres Cantos (Spain). This R&D centre is devoted to the industrialisation of HTS operations. I have been responsible of ultra-HTS campaigns from screen development to dose-response and preliminary SAR. Likewise, I have been engaged in the development and implementation of new statistical tools and assay technologies for the improvement of HTS efficiency. I have explored label-free technologies for the screening of small molecules in protein and cellular assays in a joint collaboration with external companies. More recently, I have been involved in the implementation of the strategy for drug discovery against tryponosomatids based on open innovation and collaborative research.
Dominguez, JM and Martin, JJ (2001) "Identification of a putative sordarin binding site in Candida albicans elongation factor 2 by photoaffinity labeling". Journal of Biological Chemistry 276 (33), 31402-31407
Cameron A., Martin JJ et al. (2004) “Identification and activity of a series of azole-based compounds with lactate dehydrogenase-directed anti-malarial activity”. Journal of Biological Chemistry 279 (30), 31429-31439.
Vazquez, M.J., Martin, J.J. et al. (2006) “Utilization of substrate induced quenching for screening targets promoting NADH and NADPH consumption”, J. Biomol. Screening 11 (1), 75-81.
Wood E., Martin JJ et al. (2009) “Discovery of an Inhibitor of Insulin-Like Growth Factor 1 Receptor Activation: Implications for Cellular Potency and Selectivity over Insulin Receptor”. Biochemical Pharmacology 78(12), 1438-47
Isabel Coma, Jesus Herranz, Julio Martin (2009) Statistics and Decision Making in High-Throughput Screening, in “High Throughput Screening: Methods and Protocols”, Second Edition, Editor(s): William P. Janzen, Paul Bernasconi (Springer), pp. 69-106.
Martin, J.J. (2010) “Label-free Imaging and Temporal Signature in Phenotypic Cellular Assays: A New Approach to High Content Screening”, in Currents Protocols of Pharmacology editor Terry Kenakin (Wiley-Blackwell)
Laura Vela, Peter N. Lowe, John Gerstenmaier, Lance G. Laing, Julie B. Stimmel, Lisa A. Orband-Miller and Julio J. Martin (2011) “Validation of an Optical Microplate Label-Free Platform in the Screening of Chemical Libraries for Direct Binding to a Nuclear Receptor” ASSAY and Drug Development Technologies 9 (5): 532-548
Martin JJ et al (1996) New Sordarin Derivatives for Preventing or Treating Fungal Infections, WO9614327-A1, Glaxo Wellcome SA.